Dynamics of myosin degradation in intensive care unit-acquired weakness during severe critical illness
- First Online:
Intensive care unit (ICU)-acquired muscle wasting is a devastating complication leading to persistent weakness and functional disability. The mechanisms of this myopathy are unclear, but a disturbed balance of myosin heavy chain (MyHC) is implicated.
To investigate pathways of myosin turnover in severe critically ill patients at high risk of ICU-acquired weakness.
Prospective, mechanistic, observational study.
Interdisciplinary ICUs of a university hospital.
Twenty-nine patients with Sequential Organ Failure Assessment (SOFA) scores of at least 8 on three consecutive days within the first 5 days in ICU underwent two consecutive open skeletal muscle biopsies from the vastus lateralis at median days 5 and 15. Control biopsy specimens were from healthy subjects undergoing hip-replacement surgery.
Main outcome(s) and measure(s)
Time-dependent changes in myofiber architecture, MyHC synthesis, and degradation were determined and correlated with clinical data.
ICU-acquired muscle wasting was characterized by early, disrupted myofiber ultrastructure followed by atrophy of slow- and fast-twitch myofibers at later time points. A rapid decrease in MyHC mRNA and protein expression occurred by day 5 and persisted at day 15 (P < 0.05). Expression of the atrophy genes MuRF-1 and Atrogin1 was increased at day 5 (P < 0.05). Early MuRF-1 protein content was closely associated with late myofiber atrophy and the severity of weakness.
Conclusions and relevance
Decreased synthesis and increased degradation of MyHCs contribute to ICU-acquired muscle wasting. The rates and time frames suggest that pathogenesis of muscle failure is initiated very early during critical illness. The persisting reduction of MyHC suggests that sustained treatment is required.
KeywordsICUAW MuRF-1 Myosin degradation Inflammation Muscle atrophy dmCMAP
- 5.Cheung AM, Tansey CM, Tomlinson G, Diaz-Granados N, Matte A, Barr A, Mehta S, Mazer CD, Guest CB, Stewart TE, Al-Saidi F, Cooper AB, Cook D, Slutsky AS, Herridge MS (2006) Two-year outcomes, health care use, and costs of survivors of acute respiratory distress syndrome. Am J Respir Crit Care Med 174:538–544PubMedCrossRefGoogle Scholar
- 6.Bierbrauer J, Koch S, Olbricht C, Hamati J, Lodka D, Schneider J, Luther-Schroder A, Kleber C, Faust K, Wiesener S, Spies CD, Spranger J, Spuler S, Fielitz J, Weber-Carstens S (2012) Early type II fiber atrophy in intensive care unit patients with nonexcitable muscle membrane. Crit Care Med 40:647–650PubMedCrossRefGoogle Scholar
- 17.Levine S, Biswas C, Dierov J, Barsotti R, Shrager JB, Nguyen T, Sonnad S, Kucharchzuk JC, Kaiser LR, Singhal S, Budak MT (2011) Increased proteolysis, myosin depletion, and atrophic AKT–FOXO signaling in human diaphragm disuse. Am J Respir Crit Care Med 183:483–490PubMedCentralPubMedCrossRefGoogle Scholar
- 19.Puthucheary ZA, Rawal J, McPhail M, Connolly B, Ratnayake G, Chan P, Hopkinson NS, Padhke R, Dew T, Sidhu PS, Velloso C, Seymour J, Agley CC, Selby A, Limb M, Edwards LM, Smith K, Rowlerson A, Rennie MJ, Moxham J, Harridge SD, Hart N, Montgomery HE (2013) Acute skeletal muscle wasting in critical illness. JAMA 310:1591–1600PubMedCrossRefGoogle Scholar
- 20.Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD, Glass DJ (2001) Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294:1704–1708PubMedCrossRefGoogle Scholar
- 25.Wollersheim T, Woehlecke J, Krebs M, Hamati J, Lodka D, Langhans C, Luther-Schroeder A, Haas K, Rathke T, Kleber C, Spies C, Labeit S, Schuelke M, Spuler S, Spranger J, Weber-Carstens S, Fielitz J (2013) Rapid myosin loss in intensive care unit acquired weakness. Intensive Care Med 39:228Google Scholar
- 26.Wollersheim T, Weber-Carstens S, Egbers C, Luther A, Krebs M, Hamati J, Lodka D, Kleber C, Spies C, Spuler S, Fielitz J (2012) Dynamics of skeletal muscle atrophy and atrophy gene expression in critically ill patients during ICU stay. Intensive Care Med 38:130Google Scholar
- 32.Smith IJ, Alamdari N, O’Neal P, Gonnella P, Aversa Z, Hasselgren PO (2010) Sepsis increases the expression and activity of the transcription factor Forkhead Box O 1 (FOXO1) in skeletal muscle by a glucocorticoid-dependent mechanism. Int J Biochem Cell Biol 42:701–711PubMedCentralPubMedCrossRefGoogle Scholar
- 35.Weber-Carstens S, Schneider J, Wollersheim T, Assmann A, Bierbrauer J, Marg A, Al Hasani H, Chadt A, Wenzel K, Koch S, Fielitz J, Kleber C, Faust K, Mai K, Spies CD, Luft FC, Boschmann M, Spranger J, Spuler S (2012) Critical illness myopathy and GLUT4—significance of insulin and muscle contraction. Am J Respir Crit Care Med 187:387–396PubMedCrossRefGoogle Scholar
- 37.Crossland H, Constantin-Teodosiu D, Gardiner SM, Constantin D, Greenhaff PL (2008) A potential role for Akt/FOXO signalling in both protein loss and the impairment of muscle carbohydrate oxidation during sepsis in rodent skeletal muscle. J Physiol 586:5589–5600PubMedCentralPubMedCrossRefGoogle Scholar
- 38.Dardevet D, Sornet C, Taillandier D, Savary I, Attaix D, Grizard J (1995) Sensitivity and protein turnover response to glucocorticoids are different in skeletal muscle from adult and old rats. Lack of regulation of the ubiquitin-proteasome proteolytic pathway in aging. J Clin Invest 96:2113–2119PubMedCentralPubMedCrossRefGoogle Scholar
- 43.Unroe M, Kahn JM, Carson SS, Govert JA, Martinu T, Sathy SJ, Clay AS, Chia J, Gray A, Tulsky JA, Cox CE (2010) One-year trajectories of care and resource utilization for recipients of prolonged mechanical ventilation: a cohort study. Ann Intern Med 153:167–175PubMedCentralPubMedCrossRefGoogle Scholar